

PCL Department Publications - 2004

"A,B,C,D"

Brands B, Blake J, Sproule BA, Gourlay D and Busto U. Prescription Opioid Use in Patients Presenting for Methadone Maintenance Treatment. *Drug Alcohol Depend.* 73:199-207, 2004.

Thompson MD, Comings DE, Abu-Ghazalah R, Jereseh Y, Lin L, Wade J, Sakurai T, Tokita S, Yoshida T, Tanaka H, Yanagisawa M, **Burnham WM**, Moldofsky H. Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity. *Am J Med Genet B (Neuropsychiatr Genet)* 129B:69-75, 2004.

Vessal M, Dugani CB, Solomon DA, **Burnham WM** and Ivy G. O. Astrocytic proliferation in the piriform cortex of amygdala-kindled subjects: a quantitative study in partial versus fully kindled brains. *Brain Res.* 1022, 47-53, 2004.

Zarrindast, M, Sahebgharani, M and **Burnham WM**. The effect of electroconvulsive shock seizures on behaviour induced by dopaminergic agonists and on immobility in the Porsolt test. *Euro. Neuropsychopharmacol.* 14, 509-514, 2004.

Murphy P, Likhodii S, Nysten K and **Burnham WM**. The Antidepressant Properties of the Ketogenic Diet. *Biol. Psychiat.* 56, 981-983, 2004.

Chan KF, Jia Z, Murphy PA, **Burnham WM**, Cortez MA, Snead OC 3rd. Learning and memory impairment in rats with chronic atypical absence seizures. *Exp Neurol.* 190, 328-36, 2004.

Likhodii SS and **Burnham WM**. The Effects of Ketone Bodies on Neuronal Excitability. In: *Epilepsy and the Ketogenic Diet*. Stafstrom, C. E. and Rho, J. M. Eds., Humana Press, 2004, pp.217-228.

Dorian P, Mangat I, Pinter A, Korley V. The burden of atrial fibrillation: should we abandon antiarrhythmic drug therapy? *J Cardio Pharmacol Therap.* 9:257-62, 2004

Hohnloser SH, Kuck KH, **Dorian P**, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *New Eng J Med.* 351:2481-8, 2004.

Parkash R, Green MS, Kerr CR, Connolly SJ, Klein GJ, Sheldon R, Talajic M, **Dorian P**, Humphries KH. Canadian Registry of Atrial Fibrillation. The association of left atrial size and

occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. *Amer Heart J.* 148:649-54, 2004.

Simpson C, **Dorian P**, Gupta A, Hamilton R, Hart S, Hoffmaster B, Klein G, Krahn A, Kryworuk P, Mitchell LB, Poirier P, Ross H, Sami M, Sheldon R, Stone J, Surkes J, Brennan FJ. Canadian Cardiovascular Society Consensus Conference. Assessment of the cardiac patient for fitness to drive: drive subgroup executive summary. *Can J Cardiol.* 20:1314-20, 2004.

Bokhari F, Newman D, Greene M, Korley V, Mangat I, **Dorian P**. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). *Circulation.* 110:112-6, 2004.

Dorian P, Bogaty P, Buller CE, O'Neill BJ, Armstrong PW. Canadian Cardiovascular Society Working Group. Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction.[erratum appears in CMAJ. 2004 Nov 23;171(11):1327]. *CMAJ.* 171:1042-4, 2004.

Bogaty P, Buller CE, **Dorian P**, O'Neill BJ, Armstrong PW. Canadian Cardiovascular Society Working Group. Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. [erratum appears in CMAJ. 2004 Nov 23;171(11):1327]. *CMAJ* 171:1039-41, 2004.

Parkash R, Tang A, Wells G, Blackburn J, Stiell I, Simpson C, **Dorian P**, Yee R, Cameron D, Connolly S, Birnie D, Nichol G. Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. *CMAJ.* 171:1053-6, 2004.

Armstrong PW, Bogaty P, Buller CE, **Dorian P**, O'Neill BJ. Canadian Cardiovascular Society Working Group. The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. *Can J Cardiol.* 20:1075-9, 2004.

Humphries KH, Kerr CR, Steinbuch M, **Dorian P**. Canadian Registry of Atrial Fibrillation investigators. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. *CMAJ* 171:741-5, 2004.

Hohnloser SH, **Dorian P**, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. *J Amer College Cardiol* 44:99-104, 2004.

Koster RW, **Dorian P**, Chapman FW, Schmitt PW, O'Grady SG, Walker RG. A randomized trial comparing monophasic and biphasic waveform shocks for external cardioversion of atrial fibrillation. *Amer Heart J.* 147:e20, 2004.

Noseworthy PA, Lashevsky I, **Dorian P**, Greene M, Cvitkovic S, Newman D. Feasibility of implantable cardioverter defibrillator use in elderly patients: a case series of octogenarians. *Pacing & Clinical Electrophysiology.* 27:373-8, 2004.

Leloirier P, Humphries KH, Krahn A, Connolly SJ, Talajic M, Green M, Sheldon R, **Dorian P**, Newman D, Kerr CR, Yee R, Klein GJ. Prognostic differences between atrial fibrillation and atrial flutter. *Amer J Cardiol.* 93:647-9, 2004.

Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM, on behalf of the SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. *Circulation* 110:3646-3654, 2004.

Dorian P, Philippon F, Thibault B, Kimber S, Sterns L, Greene M, Newman D, Gelaznikas R, Barr A, for the ASTRID Investigators. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. *Heart Rhythm* 1:540-7, 2004.

"E,F,G"

Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lanca AJ, O'Dowd BF, **George SR**. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. *J Biol Chemistry.*279:35671-8, 2004.

Lee DK, Lanca AJ, Cheng R, Nguyen T, Ji XD, Gobeil F Jr, Chemtob S, **George SR**, O'Dowd BF. Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. *J Biol Chem.* 279:7901-8, 2004.

Rashid AJ, O'Dowd BF, **George SR**, Minireview: Diversity and complexity of signaling through peptidergic G protein-coupled receptors. *Endocrinology.* 145:2645-52, 2004.

Grant DM. Pharmacogenetics and the regulation of gene transcription. *Pharmacogenetics* 14:391-3, 2004.

Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. (1984 Classical Article) *Brit J Clin Pharmacol.* 58:S788-93; discussion S794-5, 2004.

"H,I,J"

Yao Y, Koo J, Wells JW and **Hampson DR**. Expression of a truncated secreted form of the mGluR3 subtype of metabotropic glutamate receptor. *Biochem. Biophys. Res. Comm.* 319: 622-628, 2004.

Rosemond E, Wang M, Yao Y, Storjohann L, Stormann T, Johnson EC, and **Hampson DR**. Molecular Basis for the Differential Agonist Affinities of Group III Metabotropic Glutamate Receptors. *Mol Pharmacol*. 66, 1-9, 2004.

Chrystal K, Cheong K, **Harper P**. Chemotherapy of small cell lung cancer: state of the art. *Curr Opinion in Oncology*. 16:136-40, 2004.

Roblin S, Okey AB, **Harper PA**. AH receptor antagonist inhibits constitutive CYP1A1 and CYP1B1 expression in rat BP8 cells. *Biochem & Biophys Res Comm*. 317:142-8, 2004

Young T, Brailsford S, Connell C, Davies R, **Harper P** and Klein JH. Using industrial processes to improve patient care. *BMJ*. 328(7432):162-4, 2004.

Bellows CG, Pei W, **Heersche JN**. Number, frequency, self-renewal, and expansion of osteoprogenitor cells (CFU-O) in subcultured female rat vertebral cell populations. *Wound Repair & Regeneration*. 12:657-67, 2004.

Shorey S, **Heersche JN**, Manolson MF. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula. *Bone*. 35:909-17, 2004.

Elsubeihi ES, **Heersche JN**. Quantitative assessment of post-extraction healing and alveolar ridge remodelling of the mandible in female rats. *Arch Oral Biol*. 49:401-12, 2004.

Zhou Q, Matsumoto S, Ding LR, Fischer NE, **Inaba T**. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. *Life Sci*. 75: 2145-2155, 2004

Lee A, Woo J, **Ito S**. Frequency of infant adverse events associated with citalopram used during breastfeeding. *Am J Obstet Gynecol*. 190:218-221, 2004.

Rubin E, Lee A, **Ito S**. When Breast-feeding mothers need CNS-acting drugs. *Can J Clin Pharmacol* 11:e267-e273, 2004.

K. Aleksa, Halachmi, N, **Ito S.G. Koren**. Renal ontogeny of ifosfamide nephrotoxicity. *Lab Clin Med*. 144:285-93, 2004.

K. Aleksa, **Ito S** and G. Koren. Renal tubular metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels. *J Lab Clin Med.* 143:159-62, 2004.

"K"

Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuro-Psychopharmacol Biol Psychiat.* 28:849-863, 2004.

Grant DM, Tang BK, **Kalow W.** A simple test for acetylator phenotype using caffeine. 1984. [Biography. Classical Article. Historical Article. *Journal Article*] *Brit J Clin Pharmacol.* 58:S788-93; discussion S794-5, 2004.

Kalow W. Human pharmacogenomics: the development of a science. *Human Genomics.* 1:375-80, 2004.

Kalow W. Atypical plasma cholinesterase. A personal discovery story: a tale of three cities. *Can J Anaesthesia.* 51:206-11, 2004.

Furukawa Y, Filiano JJ, **Kish SJ.** Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. *Movement Disorders.* 19:1256-8, 2004.

Siegal D, Erickson J, Varoqui H, Ang L, Kalasinsky KS, Peretti FJ, Aiken SS, Wickham DJ and **Kish SJ.** Brain vesicular acetylcholine transporter in human users of drugs of abuse. *Synapse.* 52:223-32, 2004.

Mirecki A, Fitzmaurice P, Ang L, Kalasinsky KS, Peretti FJ, Aiken SS, Wickham DJ, Sherwin A, Nobrega JN, Forman HJ and **Kish SJ.** Brain antioxidant systems in human methamphetamine users. *J Neurochemistry.* 89:1396-408, 2004.

Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ and **Kish SJ.** Why is parkinsonism not a feature of human methamphetamine users? *Brain.* 127(Pt 2):363-70, 2004

Furukawa Y, **Kish SJ** and Fahn S. Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. *Ann Neurol.* 55:147-8, 2004.

Tong J, Fitzmaurice PS, Ang LC, Furukawa Y, Guttman M and **Kish SJ.** Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Ann Neurol.* 55:125-9, 2004

O'Brien L, Taddio A, Ipp M, Goldbach M and **Koren G**. Topical 4% amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella vaccination. *Pediatrics*. 114:e720-4, 2004.

Liu GX, Zhou J, Nattel S and **Koren G**. Single-channel recordings of a rapid delayed rectifier current in adult mouse ventricular myocytes: basic properties and effects of divalent cations. *J Physiol*. 556(Pt 2):401-13, 2004.

Kodirov SA, Brunner M, Nerbonne JM, Buckett P, Mitchell GF and **Koren G**. Attenuation of I(K,slow1) and I(K,slow2) in Kv1/Kv2DN mice prolongs APD and QT intervals but does not suppress spontaneous or inducible arrhythmias. *Amer J Physiol - Heart & Circulatory Physiology*. 286:H368-74, 2004.

Groner J, Wadwa P, Hoshaw-Woodard S, Hayes J, Klein J and **Koren G**. Castile RG. Active and passive tobacco smoke exposure: a comparison of maternal and child hair cotinine levels. *Nicotine & Tobacco Research*. 6:789-95, 2004.

Aleksa K, Halachmi N, Ito S and **Koren G**. Renal ontogeny of ifosfamide nephrotoxicity. *J Laboratory & Clinical Medicine*. 144:285-93, 2004.

Boskovic R, Rudic N, Danieliewska-Nikiel B, Navioz Y and **Koren G**. Is lack of morning sickness teratogenic? A prospective controlled study. *Birth Defects Res*. 70:528-30, 2004.

Bonari L, Pinto N, Ahn E, Einarson A, Steiner M and **Koren G**. Perinatal risks of untreated depression during pregnancy. [71 refs] [Journal Article. Review] *Can J Psychiat - Revue Canadienne de Psychiatrie*. 49:726-35, 2004.

Folco EJ, Liu GX and **Koren G**. Caveolin-3 and SAP97 form a scaffolding protein complex that regulates the voltage-gated potassium channel Kv1.5. *Amer J Physiol - Heart & Circulatory Physiology*. 287(2):H681-90, 2004.

Chan D, Klein J, Karaskov T and **Koren G**. Fetal exposure to alcohol as evidenced by fatty acid ethyl esters in meconium in the absence of maternal drinking history in pregnancy. *Ther Drug Monitoring*. 26(5):474-81, 2004.

Kozer E, Seto W, Verjee Z, Parshuram C, Khattak S, **Koren G** and Jarvis DA. Prospective observational study on the incidence of medication errors during simulated resuscitation in a paediatric emergency department. *BMJ*. 329(7478):1321, 2004.

Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, **Koren G** and Rutka JA. Intratympanic gentamicin for Meniere's disease: a meta-analysis *Laryngoscope*. 114(12):2085-91, 2004.

Nava-Ocampo AA, Velazquez-Armenta Y, Brien JF and **Koren G**. Elimination kinetics of ethanol in pregnant women. *Reproductive Toxicology*. 18(4):613-7, 2004.

- Klein J, Blanchette P and **Koren G**. Assessing nicotine metabolism in pregnancy--a novel approach using hair analysis. *Forensic Science Int.* 145(2-3):191-4, 2004.
- Bar-Oz B, Levichek Z, Moretti ME, Mah C, Andreou S and **Koren G**. Pregnancy outcome following rubella vaccination: a prospective controlled study. *Am J Med Genetics. Part A.* 130:52-4, 2004.
- Einarson A, Bonari L and **Koren G**. Pregnancy and antidepressant counseling. *Amer J Psychiat.* 161(11):2137, 2004.
- Einarson A, Bonari L, Sarkar M, McKenna K and **Koren G**. Exposure to sibutramine during pregnancy: a case series. *Eur J Obstet Gynecol Reprod Biol.* 116:112, 2004.
- Laslo-Baker D, Barrera M, Knittel-Keren D, Kozer E, Wolpin J, Khattak S, Hackman R, Rovet J and **Koren G**. Child neurodevelopmental outcome and maternal occupational exposure to solvents. *Arch Pediatrics Adolescent Medicine.* 158:956-61, 2004.
- Koren G** and Maltepe C. Pre-emptive therapy for severe nausea and vomiting of pregnancy and hyperemesis gravidarum. *J Obstet Gynaecol.* 24:530-3, 2004.
- Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP and **Koren G**. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG.* 111:940-3, 2004.
- Nulman I, Rovet J, Kennedy D, Wasson C, Gladstone J, Fried S and **Koren G**. Binge alcohol consumption by non-alcohol-dependent women during pregnancy affects child behaviour, but not general intellectual functioning; a prospective controlled study. *Archives of Women's Mental Health.* 7(3):173-81, 2004.
- Baggley A, Navioz Y, Maltepe C and **Koren G**. Einarson A. Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically. *J Midwifery & Women's Health.* 49(4):350-4, 2004
- Goldman RD, **Koren G**. Amphotericin B nephrotoxicity in children. *J Pediatric Hematol/Oncol.* 26(7):421-6, 2004.
- Chan D, Knie B, Boskovic R and **Koren G**. Placental handling of fatty acid ethyl esters: perfusion and ubcellular studies. *J Pharmacol &amm; Exp Ther.* 310(1):75-82, 2004.
- Chan D, Klein and **Koren G**. Validation of meconium fatty acid ethyl esters as biomarkers for prenatal alcohol exposure. *J Pediatrics.* 144(5):692, 2004.
- Koren G**, Avner M, Shear N. Generic isotretinoin: a new risk for unborn children. *CMAJ.* 170(10):1567-8, 2004.

Chow LM, Capra M, Levichek Z, **Koren G**, Grant RM. Toxic ingestion of 6-mercaptopurine by young siblings of pediatric oncology patients. *J Pediatrics*. 144(5):669-71, 2004.

Einarson A, Park A and **Koren G**. How physicians perceive and utilize information from a teratogen information service: the Motherisk Program. *BMC Medical Education*. 4(1):6, 2004.

Ratnapalan S, Bona N, Chandra K and **Koren G**. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. *Amer J Roentgenology*. 182(5):1107-9, 2004.

Eisen JS, **Koren G**, Juurlink DN, Ng VL. N-acetylcysteine for the treatment of clove oil-induced fulminant hepatic failure. *Journal of Toxicology - Clinical Toxicology*. 42(1):89-92, 2004.

Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. *Arch Pediatrics & Adolescent Med*. 158(4):307-8, 2004.

Bennett HA, Einarson A, Taddio A, **Koren G**, Einarson TR. Prevalence of depression during pregnancy: systematic review. *Obstet & Gynecol*. 103:698-709, 2004.

Bar-Oz B, Levichek Z and **Koren G**. Medications that can be fatal for a toddler with one tablet or teaspoonful: a 2004 update. *Paediatric Drugs*. 6(2):123-6, 2004.

Aleksa K, Ito S, **Koren G**. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. *J Laboratory & Clin. Med*. 143(3):159-62, 2004.

Koren G, Maltepe C, Navioz Y, Wolpin J. Recall bias of the symptoms of nausea and vomiting of pregnancy. *Amer J Obstetrics & Gynecology*. 190:485-8, 2004.

Fried S, Kozer E, Nulman I, Einarson TR and **Koren G**. Malformation rates in children of women with untreated epilepsy: a meta-analysis. *Drug Safety*. 27(3):197-202, 2004.

Snijdelaar DG, **Koren G**, Katz J. Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study. *Anesthesiology*. 100(1):134-41, 2004.

Koren G, Caprara D, Jacobson S, Chan D and Porter K. Is it all right to drink a little during pregnancy? *Can. Family Physician*. 50:1643-4, 2004.

Koren G. Breakthrough in treating gestational diabetes mellitus. *Op cit*. 50:987, 2004.

Hancock R, **Koren G**. Celiac disease during pregnancy. *Op cit*. 50:1361-3, 2004.

Bonari L, Bennett H, Einarson A and **Koren G**. Risks of untreated depression during pregnancy. *Op cit*. 50:37-9, 2004.

Einarson A and **Koren G**. New antidepressants in pregnancy. *Op cit.* 50:227-9, 2004.

Nava-Ocampo AA, Soldin OP and **Koren G**. Hypothyroidism during pregnancy. *Op cit.* 50:549-51, 2004.

Ahn E, Nava-Ocampo AA and **Koren G**. Multivitamin supplements for pregnant women. New insights. *Op cit.* 50:705-6, 2004.

Talaie H, Nava-Ocampo AA and **Koren G**. Antiretroviral treatment of maternal HIV infection. *Op cit.* 50:865-8, 2004.

Guttman R, Goldman RD and **Koren G**. Appendicitis during pregnancy. *Op cit.* 50:355-7, 2004.

Oren D, Nulman I, Makhija M, Ito S and **Koren G**. Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk? *Op cit.* 50:1083-5, 2004.

Koren G, Selby P and Kapur B. Is a fetus a non-consenting patient? *Op cit.* 50:1219-21, 2004.

"L"

Lee DK, **Lança AJ**, Cheng R, Nguyen T, Ji XD, Gobeil Jr., F, Chemtob S, George SR, O'Dowd BF. Agonist-independent nuclear localization of the apelin, angiotensin AT1 and Bradykinin B2 receptors. *J Biol Chem.* 279(9): 7901-7908, 2004.

Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, **Lança AJ**, O'Dowd BF and George SR. Dopamine D1 and D2 Receptor co-activation generates a novel phospholipase C-mediated calcium signal. *J Biol Chem.* 279(34): 35671-35678, 2004.

Lancôt KL, Herrmann N, Einarson TR. Drug therapy for Alzheimer's disease. *CMAJ* 27;170(9):1372; 2004.

Herrmann N, Mamdami M, **Lancôt KL**. Atypical antipsychotics and risk of cerebrovascular accidents. *Am J Psychiat.* 161:1113-5; 2004.

Herrmann N, **Lancôt KL**, Eryavec G, Khan LR. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. *J Psychopharmacol.* 18(2):215-20; 2004.

Herrmann N, **Lancôt KL**, Eryavec G, van Reekum R, Khan LR. Growth hormone response to clonidine predicts aggression in Alzheimer's disease. *Psychoneuroendocrinol.* 29:1192-1197, 2004.

Lanctôt KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia (BPSD). *Can J Psychiat.* 49:439-53, 2004.

Thompson S, **Lanctôt KL**, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. *Expert Opinion on Drug Safety*; 3(5):425-40, 2004.

Herrmann N, **Lanctôt KL**, Khan LR. The role of norepinephrine in the behavioural and psychological symptoms of dementia. *J Neuropsychiat Clin Neurosci.*; 16:261-76, 2004.

Lanctôt KL, Herrmann N, Nadkarni N, Leibovitch FS, Caldwell C, Black SE. Medial temporal hypoperfusion and aggression in Alzheimer's disease. *Arch Neurol.* 61:1723-1729, 2004.

Funk D, Vohra S, **Le AD**. Influence of stressors on the rewarding effects of alcohol in Wistar rats: studies with alcohol deprivation and place conditioning. *Psychopharmacol.* 176(1):82-7, 2004.

Shram MJ, Bahroos M, Beleskey JI, Tampakeras M, **Le AD**, Tomkins DM. Motor impairing effects of ethanol and diazepam in rats selectively bred for high and low ethanol consumption in a limited-access paradigm. *Alcoholism: Clin & Exper Res.* 28(12):1814-21, 2004.

Corson TW, Woo KK, **Li PP**, Warsh JJ Cell-type specific regulation of Calreticulin and Bcl-2 expression by mood stabilizer drugs. *Eur Neuropsychopharmacol.* 14:143-150, 2004.

Wasserman MJ, Corson TW, Sibony D, Pennefather P, **Li PP**, Warsh J.J. Chronic lithium treatment attenuates intracellular calcium mobilization in B lymphoblasts. *Neuropsychopharmacol.* 29:759-769, 2004.

Andreopoulos S, Wasserman M, Woo, K, **Li PP**, Warsh JJ. Chronic lithium treatment of B-lymphoblasts from bipolar disorder patients reduces transient receptor potential channel 3 levels. *The Pharmacogenomics J.* 4:365-373, 2004.

Li P.P. Transcriptional mechanisms of lithium action: Therapeutic implications. *Clin Neurosci Res.* 4:271-280, 2004.

Warsh JJ, Andreopoulos S, **Li PP**. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status, *Clin Neurosci Res.* 4:201-213, 2004.

"M"

Caraiscos VB, Newell JG, You-Ten KE, Elliott EM, Rosahl TW, Wafford KA, **MacDonald JF**, Orser BA. Selective enhancement of tonic GABAergic inhibition in murine hippocampal neurons by low concentrations of the volatile anesthetic isoflurane. *J. Neurosci.* 24(39):8454-8; 2004.

Xiong ZG, Zhu XM, Chu XP, Minami M, Hey J, Wei WL, **MacDonald JF**, Wemmie JA, Price MP, Welsh MJ, Simon RP. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. *Cell.* 118(6):687-98;

Caraiscos VB, Elliott EM, You-Ten KE, Cheng VY, Belelli D, Newell JG, Jackson MF, Lambert JJ, Rosahl TW, Wafford KA, **MacDonald JF**, Orser BA. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. *Proc Natl Acad Sci USA.* 101(10):3662-7; 2004.

McPherson JP, Tamblyn L, Elia A, Migon E, Shehabeldin A, Matysiak-Zablocki E, Fish J, Kassam F, Lemmers B, Salmena L, Wakeham A, You-Ten A, Prakash Hande M, Bruneau BG and Hakem R: Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. *The EMBO J.* 23: 3677-3688; 2004.

McPherson JP, Lemmers B, Chahwan R, Pamidi R, Migon E, Matysiak-Zablocki E, Moynahan ME, Essers J, Hanada K, Poonepalli A, Sanchez-Sweatman O, Khokha R, Kanaar R, Jasin M, Hande MP, and Hakem R. Involvement of Mammalian Mus81 in Genome Integrity and *Tumor Suppression.* *Sci.* 304: 1822-1826; 2004.

McPherson JP, Lemmers B, Hirao A, Migon E, Matysiak-Zablocki E, Sanchez-Sweatman O, Karaskova J, Abraham J, Hakem A, Tamblyn L, Bouchard D, Khokha R, Squire J, Hande MP, Mak TW, and Hakem R. Collaboration of Brca1 and Chk2 in tumorigenesis. *Genes & Dev.* 18: 1144-1153; 2004.

Tapp DW, Siwak CT, Head E, Cotman CW, Murphey H, Muggenberg BA, Ikeda-Douglas C & **Milgram NW**. Concept Abstraction in the Dog: development of a protocol using successive discrimination and size concept tests. *Beh Brain Res.* 150, 199-210, 2004.

Araujo JA, Chan ADF, Winka L, Seymour PA and **Milgram NW**. Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. *Psychopharmacol.* 175(1): 92-88.

Milgram NW, Head E, Zicker S, Muggenberg B, Siwak C, Tapp D & Cotman CW. Effect of an antioxidant diet, cognitive enrichment and age on size discrimination learning and reversal learning in beagle dogs. *Exper. Gerontology* 39, 753-755; 2004.

Araujo J, Studzinski CM, Larson BT & **Milgram NW** . Palatability of Two Similar Foods: A comparison of the cognitive palatability assessment protocol (CPAP) and the two-pan test. *Amer J Veterinary Res.* 65(11):1490-1496; 2004.

Araujo J & **Milgram NW**. A novel cognitive palatability assessment protocol for dogs. *J Animal Sci.* 82(7):2200-8; 2004.

Ikeda-Douglas CJ, Zicker SC, Estrada J, Jewell DE, **Milgram NW**. Prior experience, antioxidants, and mitochondrial cofactors improve cognitive function in aged beagles. *J Veterinary Therapeutics.* 5, 5-16 ; 2004.

Tapp PD, Siwak CT, Gao FQ, Chiou JY, Black SE, Head E, Muggenberg BA, Cotman CW, **Milgram NW**, Su MY. Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. *J Neurosci.* 22: 8205-13; 2004.

Tapp DW, Siwak CT, Head E, Cotman CW, Murphey H, Muggenberg BA, Ikeda-Douglas C & **Milgram NW**. Concept Abstraction in the Dog: development of a protocol using successive discrimination and size concept tests. *Beh Brain Res.* 150, 199-210 ; 2004.

Oh PI, Cohen EA, **Mittmann N**, Seung SJ. The economics of adjunctive therapies in coronary angioplasty: drugs, devices or both? *Can J Clin Pharmacol.* 11(2)Fall 2004:e202-e211, September 1, 2004

Mittmann N, Oh PI, Walker SE, Bartle WR. Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: Impact of bioavailability on costs and outcomes. *Pharmacoeconomics* (10):671-683; 2004.

Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. *Drug Safety.* 27(7):477-487; 2004.

Mydlarski PR, **Mittmann N**, Shear N. Intravenous immunoglobulin: use in dermatology. *Skin Therapy Letters* 9(5):1-6; 2004.

Mittmann N, Knowles SR, Seung SJ, Cornish W, Oh PI, Paton T. A pharmacy and therapeutics perspective on medical marijuana use in the Canadian health system. *Can J Hospital Pharmacy;* 57(3):165-172; 2004.

Schortt R, Gomez M, **Mittmann N**, Cartotto R. Intravenous Immunoglobulin (IVIg) does not improve outcome in patients with toxic epidermal necrolysis. *Burn Care and Rehabilitation*; 25:246-255; 2004.

Le L, Thiessen JJ, Erlichman C, Manzo J, Pillon L, Eisenhauer EA, **Moore MJ**. A phase I clinical and pharmacokinetic study of fostreicin in patients with advanced solid tumors. *Invest New Drugs* 22: 159-167, 2004.

Knox JJ, Oza A, Siu LL, Hedley D, **Moore MJ**. Gemcitabine concurrent with continuous infusional 5-FU in advanced bile duct cancer. *Ann Oncol*. 15:770-774, 2004.

Michael M, Brittain M, Feld R, Hedley D, Oza A, Siu LL, Oza A, **Moore MJ**. Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea. *J Clin Oncol*. 4410-4417, 2004.

Brierley J, D'Souza N, Cummings B, Ringash J, Kim J, Catton P, Wong R, **Moore MJ**, Pintilie M, Wong CS. Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum. *Acta Radiologica* 43:567-570, 2004.

"N"

Neuman MG. Signalling for inflammation and repair in inflammatory bowel disease. *Rom J Gastroenterol*. 13(4):309-16, 2004.

Jacobson-Brown P, **Neuman MG**. Colorectal polyposis and immune-based therapies. *Can J Gastroenterol*. 18(4):239-49, 2004.

Neuman MG. Cytokines--central factors in alcoholic liver disease. *Alcohol Res Health*. 2003;27(4): 307-16.

Setnik B, Souza FG, d'Almeida D, **Nobrega JN**. Increased homocysteine levels associated with gender and stress in the learned helplessness model of depression. *Pharmacol Biochem & Beh*. 77, 155-161; 2004.

Setnik B, **Nobrega JN**. Long-chain acyl-CoA synthetase-2 mRNA: Increased cerebral cortex expression in an animal model of depression. *Progress in Neuropsychopharmacol. & Biol Psychiat*. 28: 577-582; 2004.

Mamo D, Remington G, **Nobrega JN**, Hussey D, Chirakal R, Wilson .A, Baker G, Houle S and Kapur S. The effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. *Synapse*. 52, 153-162; 2004.

Mirecki A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, Sherwin A, **Nobrega JN**, Forman HJ and Kish SJ. Brain antioxidant systems in human methamphetamine users. *J Neurochem*. 89,1396-1408; 2004.

Nobrega JN, Parkes JH, Wong P, Raymond R, and Richter A. Altered expression of enkephalin and dynorphin mRNA in a genetic model of paroxysmal dystonia. *Brain Res*. 1015, 87-95; 2004.

"O"

Eghbal MA, Tafazoli S, Pennefather P, **O'Brien PJ**. Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH. *Chemico-Biol Interacns*. 151, 43-51; 2004.

O'Brien PJ, Chan K, Silber P Human and animal hepatocytes in vitro with extrapolation in vivo. *Chemico-Biol Interacns*. 150, 97-114; 2004.

Tafazoli S and **O'Brien PJ**. Prooxidant activity and cytotoxic effects of indole-3-acetic acid derivative radicals. *Chemical Res in Toxicol*. 17,1350-1355; 2004.

Siraki AG, Chan TS, **O'Brien PJ**. Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. *Toxicological Sci*. 81,148-159; 2004

Shangari N, **O'Brien PJ** The cytotoxic mechanism of glyoxal involves oxidative stress. *Biochem Pharmacol*. 68,1433-1442; 2004.

Sabzevari O ,Galati G, Moridani MY, Siraki A , **O'Brien PJ**. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. *Chem Biol Interacn*. 148,57-67; 2004

Eghbal MA, Pennefather, **O'Brien PJ**. Hydrogen sulfide cytotoxicity mechanism involves reactive oxygen species formation and mitochondrial and mitochondrial depolarization. *Toxicol*. 203,69-76; 2004.

Galati G , **O'Brien PJ**. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. *Free Rad Biol Med*. 37, 287-303; 2004.

Chan TS, Wilson JX, **O'Brien PJ**. Glycogenolysis is directed towards ascorbate synthesis by glutathione conjugation. *Biochem Biophys Res Comm*. 317, 149-156; 2004.

Chan TS, Wilson JX, **O'Brien PJ**. Coenzyme Q Cytoprotective Mechanisms. *Methods Enzymol.* 382, 89-104; 2004.

Siraki AG, Chevaldina T, Moridani MY, and **O'Brien PJ**. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening. *Curr Opin Drug Discov. Dev.* 7, 118-125; 2004.

Moridani MY, Siraki AG, Scobie H, and **O'Brien PJ**. Quantitative structure-toxicity relationships for catechols in isolated rat hepatocytes. *Chem-Biol Interact.* 147, 297-37; 2004.

Tafazoli S and **O'Brien PJ**. Prooxidant activity and cytotoxic effects of indole-3-acetic acid derivative radicals. *Chem Res Toxicol.* 17, 1350-1355; 2004.

Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lanca AJ, **O'Dowd BF**, George SR. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. *J Biol Chem.* 279(34):35671-8, 2004.

Lee DK, Lanca AJ, Cheng R, Nguyen T, Ji XD, Gobeil F Jr, Chemtob S, George SR, **O'Dowd BF**. Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. *Op cit.* 279:7901-8, 2004.

Rashid AJ, **O'Dowd BF**, George SR. Mini review: Diversity and complexity of signaling through peptidergic G protein-coupled receptors. *Endocrinol.* 145:2645-52, 2004.

Roblin S, **Okey AB** & Harper PA. AH receptor antagonist inhibits constitutive CYP1A1 and CYP1B1 expression in rat BP8 cells. *Biochem & Biophys Res Comm.* 317:142-148, 2004.

Boutros PC, Moffat ID, Franc MA, Tijet N, Tuomisto J, Pohjanvirta R & **Okey AB**. Dioxin-responsive AHRE-II gene battery: identification by phylogenetic footprinting. *Op cit.* 321:707-715, 2004.

Boutros PC & **Okey AB**. PUNS: Transcriptomic- and genomic- "in silico PCR" for enhanced primer design. *Bioinformatics.* 20:2399-2400, 2004.

Nebert DW, Dalton, P, **Okey AB**, Gonzalez F. Role of aryl hydrocarbon receptor-mediated induction of CYP1A1, CYP1A2 and CYP1B1 in environmental toxicity and cancer. *J Biol Chem.* 279:23847-23851, 2004.

"P,Q"

Buck S, **Pennefather PS**, Xue HY, Grant J, Cheng YL, Allen CJ. Engineering lipobeads: properties of the hydrogel core and the lipid bilayer shell. *Biomacromolecules*. 5:2230-7, 2004.

Ng CC, Cheng YL, **Pennefather PS**. Properties of a self-assembled phospholipid membrane supported on lipobeads. *Biophysical J*. 87(1):323-31, 2004.

Eghbal MA, **Pennefather PS**, O'Brien PJ. H₂S cytotoxicity mechanism involves reactive oxygen species formation and mitochondrial depolarisation. *Toxicology*. 203(1-3):69-76, 2004.

Gyulkhandanyan AV, **Pennefather PS**. Shift in the localization of sites of hydrogen peroxide production in brain mitochondria by mitochondrial stress. *J Neurochem*. 90(2):405-21, 2004.

Park PS, Ng CC, Buck S, Wells JW, Cheng YL, **Pennefather PS**. Characterization of radioligand binding to a transmembrane receptor reconstituted into Lipobeads. *FEBS Letters*. 567(2-3):344-8, 2004.

Wasserman MJ, Corson TW, Sibony D, Cooke RG, Parikh SV, **Pennefather PS**, Li PP, Warsh JJ. Chronic lithium treatment attenuates intracellular calcium mobilization. *Neuropsychopharmacol*. 29(4):759-69, 2004.

Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. *Biol Psychiat*. 55(10):965-70; 2004.

Kan PX, Pependikyte V, Kaminsky ZA, Yolken RH, and **Petronis A**. Epigenetic studies of genomic retroelements in major psychosis. *Schizophrenia Res*. 67: 95-106; 2004.

Fuke C, Shimabukuro M, **Petronis A**, Sugimoto J, Oda T, Miura K, Miyazaki T, Ogura C, Okazaki Y, and Jinno Y. Age related changes of the 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. *Ann Human Gen*. 68(Pt 3):196-204; 2004.

Sivagnanasundaram S, Broman KW, Liu M, **Petronis A**. Quasi-linkage: a confounding factor in linkage analysis of complex diseases? *Human Genetics*, 114: 588-93; 2004.

Petronis A. Neurodevelopment, schizophrenia, and epigenetics. In: *Neurodevelopment and Schizophrenia*. Eds: M. Keshavan, J.L. Kennedy, Murray R. Oxford University Press, 174-190; 2004.

"R,S"

Riddick DS, Lee C, Bhatena A, Timsit YE, Cheng P-Y, Morgan ET, Prough RA, Ripp SL, Michael Miller KK, Jahan A, Chiang JYL: Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. *Drug Metab Dispos.* 32: 367-375; 2004.

Seth R, Yang S, Choi S, Sabeen M, **Roberts EA**: In vitro assessment of copper-induced toxicity in the human hepatoma line, Hep G2. *Toxicol in Vitro.* 18:501-509; 2004.

Narindrasorasak S, Zhang X-F, **Roberts EA**, Sarkar B. Comparative analysis of metal binding characteristics of copper chaperone proteins, Atx1 and Atox1. *Bioinorg Chem Appl.* 2:105-123; 2004.

Smith SD, She Y-M, **Roberts EA**, Sarkar B: Using immobilized metal affinity chromatography, two-dimensional electrophoresis and mass spectrometry to identify hepatocellular proteins with copper-binding ability. *J Proteome Res.* 3:834-840 ; 2004.

Roberts EA: Hepatitis B, the next generation. *Pediatr Res.* 56:318-20 (e-published July 2004).

Roberts EA: Editorial: Hepatitis B and C in children. *Int Semin Pediatr Gastroenterol Hepatol Nutr.* 12(4):1-2 ; 2004..

Chang M-H, Hadzic D, Heller S, Joans M, Kohn IJ, Negro F, **Roberts EA**, Sibal A: Acute and chronic hepatitis. Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr.* 39 (Suppl 2) S584-S588; 2004.

Roberts EA: Drug-induced hepatotoxicity in children. In: *Pediatric Gastrointestinal Disease: Patho-physiology, Diagnosis, Management*, Walker WA, Goulet O, Kleinman RE, Sherman PM, Shneider BL, Sanderson IR, eds, 4th edition, B.C. Decker, Hamilton. pp. 1219-1240; 2004.

Al-Hakim, A, Rui, X, Tsao, J, Albert, PR, **Schimmer, BP**: Forskolin-resistant Y1 adrenal cell mutants are deficient in adenylyl cyclase type 4. *Mol Cell Endocrinol* 214: 155-165 ; 2004.

Rui, X, Al-Hakim, A, Tsao, J, Albert, PR, **Schimmer, BP**: Expression of adenylyl cyclase-4 (AC-4) in Y1 and forskolin-resistant adrenal cells. *Mol Cell Endocrinol* 215: 101-108; 2004.

Rainey, WE, Saner, K, **Schimmer, BP**: Adrenocortical cell lines. *Mol Cell Endocrinol.* 228: 23-28; 2004.

Silvestri S, Negrete JC, Seeman M, Shammi CM and **Seeman P**: Does nicotine affect D2 receptor upregulation? *Acta Psychiatrica Scand.* 109: 313-317; 2004.

Seeman P, Tallerico T and Ko F.: Alcohol-withdrawn animals have a prolonged increase in dopamine D2High receptors, reversed by general anesthesia: relation to relapse? *Synapse* 52: 77-83; 2004.

Seeman P: Diverse psychotomimetics act through a common signaling pathway. *Science* 305: 180; 2004. (One-page publication)

Seeman P: Atypical antipsychotics: Mechanism of action. *Focus* 2: 48-58; 2004.

Schoedel KA, Hoffmann EB, Rao Y, **Sellers EM** and Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics.* 14(9):615-26, 2004.

Mamo D, Sedman E, Tillner J, **Sellers EM**, Romach MK and Kapur S. EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. *Psychopharmacology.* 175(3):382-8, 2004.

Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ and **Sellers EM**. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. *J Clinical Pharmacol.* 44(10):1132-42, 2004.

Kim MJ, Nafziger AN, Zhang Y and **Sellers EM**. Gaedigk A. Bertino JS Jr. Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. *Op cit.* 44:966-73, 2004.

Ross LE, **Sellers EM**, Gilbert Evans SE and Romach MK. Mood changes during pregnancy and the postpartum period: development of a biopsychosocial model. *Acta Psychiatrica Scandinavica.* 109(6):457-66, 2004.

Sayeh E, Sterling K, Speck E, Freedman J, **Semple JW**. IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells.[erratum appears in Blood. 103(10):3643]. *Blood.* 103(7):2705-9, 2004

Semple JW. Leucodepletion and immune response mechanisms. *Vox Sanguinis.* 87 Suppl 2:136-8, 2004

Sayeh E, Aslam R, Speck ER, Le-Tien H, Lazarus AH, Freedman J and **Semple JW**. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype. *Transfusion.* 44(11):1572-8, 2004.

Semple JW, Duncker BP. ORC-associated replication factors as biomarkers for cancer. *Biotechnology Advances*. 22(8):621-31, 2004.

Gharbi K, **Semple JW**, Ferguson MM, Schulte PM and Danzmann RG. Linkage arrangement of Na,K-ATPase genes in the tetraploid-derived genome of the rainbow trout (*Oncorhynchus mykiss*). *Animal Genetics*. 35(4): 321-5, 2004.

Fast LD, **Semple JW**, DiLeone G, Kim M, Freedman J and Chapman J. Purmal A. Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs. *Transfusion*. 44(2):282-5, 2004.

Romanus D, Iscoe N, Deangelis C, **Shear N**, Einarson TR. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. *Supportive Care in Cancer*. 12 (12):844-51, 2004.

Iskedjian M, Piwko C, **Shear NH**, Langley RG, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. *Amer J Clin Dermatol*. 5(4):267-79, 2004.

Walsh SR, **Shear NH**. Psoriasis and the new biologic agents: interrupting a T-AP dance. *CMAJ*. 170:1933- 41, 2004.

Shear NH, Redelmeier DA, Callen JP. Ad Hoc Task Force of the American Academy of Dermatology on the Reported Link Between Antibiotic Use and Breast Cancer. Use of antibiotics and risk of cancer. *JAMA*. 291(22):2699, 2004.

Mydlarski PR, Mittmann N, **Shear NH**. Intravenous immunoglobulin: use in dermatology. *Skin Therapy Letter*. 9(5):1-6, 2004.

Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, **Shear NH**. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. *Drug Safety*. 27(7):477-87, 2004.

Koren G, Avner M, **Shear N**. Generic isotretinoin: a new risk for unborn children. *CMAJ*. 170(10):1567-8, 2004

Wong GA, **Shear NH**. Is a drug alone sufficient to cause the drug hypersensitivity syndrome? *Archives of Dermatol*. 140(2):226-30, 2004

"T"

Toal CB. Formulation dependent pharmacokinetics - Does the dosage form matter for nifedipine? *J. Cardiovasc Pharmacol.* 44:82-86; 2004.

Shram MJ, Bahroos M, Beleskey JI, Tampakeras M, Le AD, **Tomkins DM.** Motor impairing effects of ethanol and diazepam in rats selectively bred for high and low ethanol consumption in a limited-access paradigm. *Alcohol Clin Exp Res.* 28(12):1814-21; 2004.

Dempsey D, Tutka D, Jacob, III, P, Allen F, Schoedel K, **Tyndale RF,** Benowitz NL. Nicotine metabolite ratio as an index of CYP2A6 metabolic activity. *Clin Ther Pharmacol.* 76(1):64-72; 2004.

McKeown-Eyssen G, Baines C, Cole D, Riley N, **Tyndale RF,** Marshall L, Jazmaji V. Case-Control Study of Genotypes in Multiple Chemical Sensitivity: CYP2D6, NAT1, NAT2, PON1, and PON2. *Int'l J of Epidemiolo.* 33:1-8; 2004.

De Luca V, Wong AHC, Muller DJ, Wong GWH, **Tyndale RF,** Kennedy JL. Evidence of association between smoking and the alpha7-nicotinic receptor subunit gene in schizophrenia patients. *Neuropharmacology* 29(8): 1522-6; 2004.

Schoedel KA, Hoffmann EB, Xu B, Rao Y, Sellers EM, **Tyndale RF.** Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics.* 14: 615-626; 2004.

Swan GE, Benowitz NL, Jacob III P, Lessov CN, **Tyndale RF,** Wilhelmsen K, Krasnow RE, McElroy MR, Moore SE, Wambach M Pharmacogenetics of nicotine metabolism in twins: methods and procedures. *Twin Research* 7 (5): 435-482; 2004.

O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, Wong S, Hanley J, **Tyndale RF.** Genetically decreased CYP2A6 increases the risk of onset of tobacco dependence: a prospective study of young adolescents. *Tobacco Control* 13(4):422-428; 2004.

Tyndale RF, Hoffmann E, Xu B, Shields PG, Benowitz N, Lerman C. Genetic variation in CYP2A6 alters nicotine plasma levels in subjects treated with nicotine patch. *Nicotine and Tobacco Res.* 6(4); 738; 2004.

S Miksys and **Tyndale RF.** The unique regulation of brain cytochrome P450 2 (CYP2) family by drugs and genetics. *Drug Metabolism Reviews.* 36: 1-21; 2004.

"U,V"

Shenton JM, Chen J, **Utrecht JP**: Animal models of idiosyncratic drug reactions. *Chemico-Biol. Interact.* 150:53-70, 2004.

Utrecht JP: Drug-Induced Lupus Erythematosus; In: *Cutaneous Lupus Erythematosus*, Kuhn A, Lehmann P and Ruzicka T (eds), Springer, Berlin, 2004.

Masson MJ, Teranishi M, Shenton J, **Utrecht, J**: Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat. *J. Immunotoxicol.* 1: 79-93, 2004.

Masson, MJ, **Utrecht JP**: Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. *Chem Res Toxicol* 17 (1): 82-94 (2004).

Sequin B, Masson, MJ, **Utrecht J**: D-Penicillamine-induced Autoimmunity in the Brown Norway Rat: Role for Both T and non-T Splenocytes in Adoptive Transfer of Tolerance. *Op cit.* 17(10): 1299-1302, 2004.

Popovic M, Nierkens S, Pieters R, **Utrecht J**: Investigating the role of 2-phenyl-propenal in felbamate- induced idiosyncratic drug reactions. *Op cit.* 17: 1568-1576, 2004.

Wong AH, Trakalo J, Likhodi O, Yusuf M, Macedo A, Azevedo MH, Klempan T, Pato MT, Honer WG, Pato CN, **Van Tol HHM**, & Kennedy JL: Association between schizophrenia and the syntaxin 1A gene. *Biol Psychiat.* 56(1):24-9; 2004.

Sanyal S, Wintle RF, Nuttley WM, Summers SH, Arvan R, Bigras E, Merz D, Hebert T, van der Kooy D, Schafer WR, Culotti GJ & **Van Tol HHM**: Dopamine modulates plasticity of distinct sensory responses in *C. elegans*. *EMBO J.* 23(2):473-82; 2004.

Suo S, Ishiura S, **Van Tol HHM**: Dopamine receptors in *C. elegans*. *Eur J Pharmacol.* 500: 159-166; 2004.

"W"

Ross BM, Hughes B, Turenne S, Seeman M and **Warsh JJ**. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. *Eur. Neuropsychopharmacol.* 14: 191-197, 2004.

Corson TW, Woo KK, Li PP, **Warsh JJ**. Cell-type Specific Regulation of Calreticulin and Bcl-2 Expression by Mood Stabilizer Drugs. *Op cit.* 14: 143-150, 2004.

Wasserman MJ, Corson TW, Li PP, Sibony D, Parikh SV, Pennefather P, and **Warsh JJ**. Chronic Lithium Treatment Attenuates Intracellular Calcium Mobilization. *Neuropsychopharmacol.*29: 759-769, 2004

Andreopoulos S, Wasserman M, Woo K, Li PP and **Warsh JJ**. Chronic Lithium Treatment of B Lymphoblasts From Bipolar Disorder Patients Reduces Transient Receptor Potential Channel 3 Levels. *Pharmacogenomics J.* 4: 365-373, 2004.

Warsh JJ, Andreopoulos S, Li PP. Role of Intercellular Calcium Signaling in the Pathophysiology and Pharmacotherapy of Bipolar Disorder: Current Status. *Clinical Neurosci. Res.* 4: 201-213, 2004.

Hu, Z and **Wells, PG**. Human interindividual variation in lymphocyte UDP-glucuronosyltransferases as a determinant of in vitro benzo[a]pyrene covalent binding and cytotoxicity. *Toxicol Sci.* 78: 32-40, 2004.

Laposa RR, Henderson JT, Xu E and **Wells PG**. Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM. *FASEB J.* 18: 896-898, 2004.

Kennedy JC, Memet S and **Wells PG**. Antisense evidence of NF-kB-dependent embryopathies initiated by phenytoin-enhanced oxidative stress. *Mol Pharmacol.* 66(3): 404-412, 2004.

Kasapinovic, S, McCallum G, Wiley MJ and **Wells PG**. The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase (iNOS) knockout mice. *Free Rad Biol Med.* 37(11): 1703-1711, 2004.

Wells PG, Mackenzie PI, Roy Chowdhury J, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Roy Chowdhury N and Ritter JR. Glucuronidation and the UDP-glucuronosyltransferases in drug therapy and disease. *Drug Metab Dispos.* 32: 281-290, 2004.

Chen CS and **Wells PG**. In utero origins of cancer: maternal dietary vitamin E, fetal oxidative DNA damage and postnatal carcinogenesis in p53 knockout mice. In: *Vitamin E and Health*, F Kelly, M Meydani and L Packer (eds.), Ann. NY Acad. Sci. 1031: 395-398, 2004.

Shinkai T, Shaikh S, Matsumoto C, De Luca V, Zai G, Arnold PD, King N, Trakalo J, Potapova N, Wong G, Hori H, Ohmori O, **Wong AHC**, Nakamura J, Kennedy JL: Association between the Pro179Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. *Psychiatric Genetics.* 14:177-180; 2004.

De Luca V, **Wong AHC**, Muller DJ, Wong GWH, Tyndale RF, Kennedy JL: Evidence of association between smoking and alpha7-nicotinic receptor subunit in schizophrenia, *Neuropsychopharmacology*. 29:1522-1526; 2004.

Wong AHC, Trakalo J, Likhodi O, Yusuf M, Macedo A, Azevedo M-H, Klempan T, Pato MT, Honer WG, Pato CN, Van Tol HHM, Kennedy JL: Association between schizophrenia and the syntaxin 1a gene. *Biol Psychiat*. 56(1):24-29; 2004.

"X,Y,Z"

Poulos C X and **Zack M**. Low dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. *Beh Pharmacol*. 15, 503-512; 2004.
